Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 5:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 129 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Tumor Infiltrating Lymphocytes Clear all
Recruiting Phase 2 Interventional

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

NCT06295159
View directory record Official record
Conditions
Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma, Melanoma
Interventions
Nivolumab, Nivolumab + Relatlimab, Ipilimumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 18, 2026, 5:28 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma

NCT01740557
View directory record Official record
Conditions
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Aldesleukin, CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, NGFR-transduced Autologous T Lymphocytes, Quality-of-Life Assessment
Biological · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 18, 2026, 5:28 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes

NCT01236573
View directory record Official record
Conditions
Skin Cancer, Metastatic Melanoma
Interventions
Fludarabine, Cyclophosphamide, IL-12 transduced TIL
Drug · Biological
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 66 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Sep 18, 2026, 5:28 PM EDT
Active, not recruiting Phase 1 Interventional

Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients

NCT05176470
View directory record Official record
Conditions
Locally Advanced Melanoma, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Stage IV Melanoma
Interventions
Cyclophosphamide, Fludarabine, Lifileucel, Pembrolizumab, Therapeutic Conventional Surgery
Drug · Biological · Procedure
Lead sponsor
Richard Wu
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 18, 2026, 5:28 PM EDT
Active, not recruiting Phase 1 Interventional

Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC

NCT05768347
View directory record Official record
Conditions
Urothelial Carcinoma, Non-Invasive Bladder Urothelial Carcinoma
Interventions
Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 18, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Results available

QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma

NCT02383498
View directory record Official record
Conditions
Chordoma
Interventions
Placebo, GI-6301 Vaccine (Yeast- Brachyury), Radiotherapy, wGT3X-BT Actigraph
Other · Biological · Radiation + 1 more
Lead sponsor
NantCell, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2024 · Synced Sep 18, 2026, 5:28 PM EDT
Terminated Phase 2 Interventional Results available

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

NCT01468818
View directory record Official record
Conditions
Metastatic Melanoma, Skin Cancer
Interventions
Cyclophosphamide, Fludarabine, Young Tumor Infiltrating Lymphocytes (TIL)
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2016 · Synced Sep 18, 2026, 5:28 PM EDT
Completed Phase 1Phase 2 Interventional

Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma

NCT00046852
View directory record Official record
Conditions
Infection, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, pneumococcal polyvalent vaccine, therapeutic autologous lymphocytes, therapeutic tumor infiltrating lymphocytes, carmustine, cyclophosphamide, melphalan, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced Sep 18, 2026, 5:28 PM EDT
Recruiting Phase 3 Interventional

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

NCT05727904
View directory record Official record
Conditions
Metastatic Melanoma, Unresectable Melanoma, Melanoma
Interventions
Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover Period
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
24
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 18, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

NCT00001832
View directory record Official record
Conditions
Melanoma, Neoplasm Metastasis
Interventions
gp100:209-217 (210M), Montanide ISA-51, IL-2, MART-1:26-35(27L), Abl cells, Fludarabine, Cyclophosphamide, GCSF (Growth colony stimulating factor), Apheresis
Drug · Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
7 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Sep 18, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Results available

Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...

NCT01319565
View directory record Official record
Conditions
Metastatic Melanoma, Skin Cancer
Interventions
Aldesleukin, Cyclophosphamide, Fludarabine, Young TIL, Total Body Irradiation (TBI)
Drug · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 66 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 18, 2026, 5:28 PM EDT
Not yet recruiting Phase 2 Interventional

Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab

NCT07720180
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 18, 2026, 5:28 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma

NCT01369888
View directory record Official record
Conditions
Metastatic Melanoma, Skin Cancer
Interventions
Cyclophosphamide, Fludarabine, Tumor Infiltrating Lymphocytes, IL-15
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 66 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Sep 18, 2026, 5:28 PM EDT
Completed Phase 1 Interventional

Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung

NCT00301730
View directory record Official record
Conditions
Breast Cancer, Metastatic Cancer
Interventions
aldesleukin, therapeutic tumor infiltrating lymphocytes, trastuzumab, paclitaxel, conventional surgery
Biological · Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Sep 18, 2026, 5:28 PM EDT
Enrolling by invitation No phase listed Observational

Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment

NCT05600933
View directory record Official record
Conditions
Solid Tumors, Hematologic Malignancy, Gastrointestinal Cancer, Liver Cancer, Pancreatic Cancer, Melanoma, Pre-Malignancy, Lung Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 18, 2026, 5:28 PM EDT
Recruiting Phase 2 Interventional

TIL Therapy in cSCC and MCC

NCT07288073
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma, Skin Cancer
Interventions
LN-145, Cyclophosphamide, Fludarabine, Interleukin-2
Biological · Drug
Lead sponsor
Karam Khaddour, MD, MS
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 18, 2026, 5:28 PM EDT
Active, not recruiting Phase 1 Interventional

Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors

NCT05902520
View directory record Official record
Conditions
HNSCC, Melanoma, Gynecologic Cancer, Colorectal Cancer, Lung Cancer, Urogenital Cancer
Interventions
DP CD8 TIL, DP CD8 TIL KD, Low dose IL-2
Biological
Lead sponsor
AgonOx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 18, 2026, 5:28 PM EDT
Terminated Phase 2 Interventional Results available

Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma

NCT00863330
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
Tumor Infiltrating Lymphocytes (TIL)
Biological
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Sep 18, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Results available

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers

NCT01585428
View directory record Official record
Conditions
Cervical Cancer, Oropharyngeal Cancer, Vaginal Cancer, Anal Cancer, Penile Cancer
Interventions
Fludarabine, Cyclophosphamide, Young TIL, Aldesleukin
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Sep 18, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Results available

Trial of pIL-12/MK-3475 in Metastatic Melanoma

NCT02493361
View directory record Official record
Conditions
Melanoma
Interventions
Pembrolizumab, pIL-12
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
San Francisco, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Sep 18, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Pembrolizumab

NCT02818920
View directory record Official record
Conditions
Non-small Cell Lung Carcinoma
Interventions
Pembrolizumab
Drug
Lead sponsor
Neal Ready MD PhD
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Rochester, Minnesota • Lebanon, New Hampshire • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 18, 2026, 5:28 PM EDT
Completed Phase 1 Interventional

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

NCT05628883
View directory record Official record
Conditions
Metastatic Melanoma, Unresectable Melanoma, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, Ocular Melanoma, Uveal Melanoma, Iris Melanoma, Conjunctival Melanoma, Non-Cutaneous Melanoma
Interventions
TBio-4101, Cyclophosphamide, Fludarabine, Interleukin-2
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 18, 2026, 5:28 PM EDT
Terminated Phase 1 Interventional

A Study of DeTIL-0255 in Adults With Advanced Malignancies

NCT05107739
View directory record Official record
Conditions
Platinum-resistant Ovarian Cancer, Endometrial Cancer, Cervical Cancer
Interventions
Drug Product De-TIL-0255
Biological
Lead sponsor
Nurix Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
New Brunswick, New Jersey • Buffalo, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Sep 18, 2026, 5:28 PM EDT
Active, not recruiting Phase 2 Interventional

Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC

NCT05645380
View directory record Official record
Conditions
Triple Negative Breast Cancer, Breast Cancer
Interventions
Carboplatin, Docetaxel, Doxorubicin, Cyclophosphamide, Pembrolizumab
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
7
States / cities
Fairway, Kansas • Kansas City, Kansas • Overland Park, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 18, 2026, 5:28 PM EDT